Literature DB >> 16507233

New strategies in the medical treatment of carotid artery disease.

Kumar Rajamani1, Seemant Chaturvedi.   

Abstract

Most patients with ischemic stroke or transient ischemic attack are screened for internal carotid artery stenosis. Although it is important to identify candidates for endarterectomy or stenting, the clinician must realize that most patients are not candidates for revascularization. Therefore, medical therapy remains the cornerstone of treatment. In this article, current thinking on medical therapy for carotid atherosclerosis is outlined, including aggressive use of statins, targeted blood pressure lowering, and antithrombotic therapy. Implementation of these therapies will likely reduce the need for revascularization procedures in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507233     DOI: 10.1007/s11886-006-0008-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  34 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.

Authors:  H C Bucher; L E Griffith; G H Guyatt
Journal:  Ann Intern Med       Date:  1998-01-15       Impact factor: 25.391

3.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 5.  Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.

Authors:  Pierre Amarenco; Julien Labreuche; Philippa Lavallée; Pierre-Jean Touboul
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

6.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

Review 7.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 8.  Modulating atherosclerosis through inhibition or blockade of angiotensin.

Authors:  Robert S Rosenson
Journal:  Clin Cardiol       Date:  2003-07       Impact factor: 2.882

9.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

10.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.